Current state and prospects for the development of the domestic pharmaceutical industry

Abstract

The main stages of the development of the Russian medical and pharmaceutical industry in 2010 are presented in the context of the dominance of large foreign companies producing medicines and medical devices in the pharmaceutical market. This reflects the political and economic restrictive measures illegally taken against Russia by the European Union, the United States of America, and some other unfriendly countries and has influenced the dynamics of the development of the medical and pharmaceutical industry in our country. To harmonize approaches to the production and quality control of medicines, this paper presents the stages of large-scale reforms on the transition of the Russian pharmaceutical industry to standards of good manufacturing practice and the implementation of state programs aimed at modernizing the industrial segment of the pharmaceutical industry. As part of the improvement of the standardization system of medicines, the study also presents the characteristics of the XIII, XIV, and XV editions of the State Pharmacopoeia of the Russian Federation published during the study period, in the development of which employees of the Military Medical Academy named after S.M. Kirov participated. The role and purpose of the creation of the developed Pharmacopoeia of the Eurasian Economic Union, approved by the Board of the Eurasian Economic Commission, is also reflected in this paper. This article describes the phased implementation of federal target programs, state programs, and other strategic plans and measures of nonfinancial support from the state, which have significantly expanded competencies in the field of development and production of medicines and medical devices and increased their output during the period analyzed. The development of medicines and increasing their production volumes with the help of pharmaceutical clusters, which acted as the “locomotives” of the industry, and various projects in establishing the production of innovative medical products with the help of the Industrial Development Fund, which increased the investment attractiveness of these sectors of the national economic complex, played an important role. The results revealed the essence of the changes concerning the revival of the activities of industrial pharmacies, considering a personalized approach to the treatment of patients. The study also presents an assessment of the Pharmaceutical industry Development Strategy for the period up to 2030.

Keywords

medicines / medical and pharmaceutical industry / standards of Good manufacturing practice / State Pharmacopoeia / Pharmacopoeia of the Eurasian Economic Union / pharmaceutical industry / pharmaceutical clusters / import substitution / production pharmacies

References

[1] Nezhnikova EV, Maksimchuk MV. Pharmaceutical industry in Russia: problems and prospects of development. RUDN journal of economics. 2019;27(1):102–112. EDN: TFHWQO doi: 10.22363/2313-2329-2019-27-1-102-112

[2] Нежникова Е.В., Максимчук М.В. Фармацевтическая отрасль в РФ: проблемы и перспективы развития // Вестник РУДН. Серия: Экономика. 2019. Т. 27, № 1. С. 102–112. EDN: TFHWQO doi: 10.22363/2313-2329-2019-27-1-102-112

[3] Nezhnikova EV, Maksimchuk MV. Pharmaceutical industry in Russia: problems and prospects of development. RUDN journal of economics. 2019;27(1):102–112. EDN: TFHWQO doi: 10.22363/2313-2329-2019-27-1-102-112

[4] Miroshnichenko YuV, Golubenko RA, Enikeeva RA. Modern aspects of the development of the pharmaceutical industry. Military medical journal. 2023;344(6):93–96. EDN: MMHUSK doi: 10.52424/00269050_2023_344_6_93

[5] Мирошниченко Ю.В., Голубенко Р.А., Еникеева Р.А. Современные аспекты развития фармацевтической отрасли // Военно-медицинский журнал. 2023. Т. 344, № 6. С. 93–96. EDN: MMHUSK doi: 10.52424/00269050_2023_344_6_93

[6] Miroshnichenko YuV, Golubenko RA, Enikeeva RA. Modern aspects of the development of the pharmaceutical industry. Military medical journal. 2023;344(6):93–96. EDN: MMHUSK doi: 10.52424/00269050_2023_344_6_93

[7] Oborin MS. Problems and prospects of import substitution in the pharmaceutical industry. Bulletin NGIEI. 2021;(5):101–110. EDN: YPGGYL doi: 10.24412/2227-9407-2021-5-101-110

[8] Оборин М.С. Проблемы и перспективы импортозамещения в фармацевтической отрасли // Вестник НГИЭИ. 2021. № 5. С. 101–110. EDN: YPGGYL doi: 10.24412/2227-9407-2021-5-101-110

[9] Oborin MS. Problems and prospects of import substitution in the pharmaceutical industry. Bulletin NGIEI. 2021;(5):101–110. EDN: YPGGYL doi: 10.24412/2227-9407-2021-5-101-110

[10] Miroshnichenko YuV, Perfiliev AB, Kostenko NL, Enikeeva RA. Historical and medical-pharmaceutical aspects of the creation of a pharmacopeia. Bulletin of the Russian Military Medical Academy. 2022;24(1):219–230. EDN: XHKWJU doi: 10.17816/brmma89024

[11] Мирошниченко Ю.В., Перфильев А.Б., Костенко Н.Л., Еникеева Р.А. Исторические и медико-фармацевтические аспекты создания фармакопеи // Вестник Российской военно-медицинской академии. 2022. Т. 24, № 1. С. 219–230. EDN: XHKWJU doi: 10.17816/brmma89024

[12] Miroshnichenko YuV, Perfiliev AB, Kostenko NL, Enikeeva RA. Historical and medical-pharmaceutical aspects of the creation of a pharmacopeia. Bulletin of the Russian Military Medical Academy. 2022;24(1):219–230. EDN: XHKWJU doi: 10.17816/brmma89024

[13] Lin AA, Sokolova SV, Bol’shakova MV. Pharmaceutical market: implementation of the import substitution strategy (Russia, St. Petersburg). Problems of modern economics. 2017;(2):181–186. EDN: ZMYZJT

[14] Лин А.А., Соколова С.В., Большакова М.В. Фармацевтический рынок: реализация стратегии импортозамещения // Проблемы современной экономики. 2017. № 2. С. 181–186. EDN: ZMYZJT

[15] Lin AA, Sokolova SV, Bol’shakova MV. Pharmaceutical market: implementation of the import substitution strategy (Russia, St. Petersburg). Problems of modern economics. 2017;(2):181–186. EDN: ZMYZJT

[16] Andreeva LV. The normative legal basis for the establishment of the common market of medicines of the Eurasian Economic Union. International Cooperation of Eurasian States: Politics, Economics, Law. 2016;(4):51–60. EDN: ZBEVGH

[17] Андреева Л.В. Нормативная правовая основа создания общего рынка лекарственных средств Евразийского экономического союза // Международное сотрудничество евразийских государств: политика, экономика, право. 2016. № 4. С. 51–60. EDN: ZBEVGH

[18] Andreeva LV. The normative legal basis for the establishment of the common market of medicines of the Eurasian Economic Union. International Cooperation of Eurasian States: Politics, Economics, Law. 2016;(4):51–60. EDN: ZBEVGH

[19] Egorova DA. Drivers for the development of the pharmaceutical industry: global trends. Modern science: actual problems of theory and practice”, a series of “Economics and law”. 2023;(2):22–26. EDN: FIAENF doi: 10.37882/2223-2974.2023.02.12

[20] Егорова Д.А. Драйверы развития фармацевтической отрасли: глобальные тренды // Современная наука: актуальные проблемы теории и практики. Серия: Экономика и право. 2023. № 2. С. 22–26. EDN: FIAENF doi: 10.37882/2223-2974.2023.02.12

[21] Egorova DA. Drivers for the development of the pharmaceutical industry: global trends. Modern science: actual problems of theory and practice”, a series of “Economics and law”. 2023;(2):22–26. EDN: FIAENF doi: 10.37882/2223-2974.2023.02.12

[22] Zavyalova EB, Polozova DV. Development prospects of the Russian pharmaceutical industry in the modern context. International business. 2023;(2):64–78. EDN: HIARBN

[23] Завьялова Е.Б., Полозова Д.В. Перспективы развития российской фармацевтической отрасли в современных условиях // Международный бизнес. 2023. № 2. С. 64–78. EDN: HIARBN

[24] Zavyalova EB, Polozova DV. Development prospects of the Russian pharmaceutical industry in the modern context. International business. 2023;(2):64–78. EDN: HIARBN

[25] Umarov SZ, Khorunzhaya AA, Tikhonov AV. Analysis of the pharmaceutical industry digital transformation: positive and negative consequences. Pharmacoeconomics: theory and practice. 2023;11(2):64–65. EDN: ZWIZAW doi: 10.30809/phe.2.2023.40

[26] Умаров С.З., Хорунжая А.А., Тихонов А.В. Анализ цифровой трансформации фармацевтической отрасли: положительные и отрицательные последствия // Фармакоэкономика: теория и практика. 2023. Т. 11, № 2. С. 64–65. EDN: ZWIZAW doi: 10.30809/phe.2.2023.40

[27] Umarov SZ, Khorunzhaya AA, Tikhonov AV. Analysis of the pharmaceutical industry digital transformation: positive and negative consequences. Pharmacoeconomics: theory and practice. 2023;11(2):64–65. EDN: ZWIZAW doi: 10.30809/phe.2.2023.40

[28] Gorobets MS. Pharmaceutical industry of the Russian Federation in the conditions of external sanctions. Bulletin of the Educational Consortium of the Middle Russian University. Series: economics and management. 2023;(21):75–77. EDN: GIDMXC

[29] Горобец М.С. Фармацевтическая промышленность Российской Федерации в условиях внешних санкций // Вестник образовательного консорциума Среднерусский университет. Серия: Экономика и управление. 2023. № 21. С. 75–77. EDN: GIDMXC

[30] Gorobets MS. Pharmaceutical industry of the Russian Federation in the conditions of external sanctions. Bulletin of the Educational Consortium of the Middle Russian University. Series: economics and management. 2023;(21):75–77. EDN: GIDMXC

RIGHTS & PERMISSIONS

Eco-Vector